This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Drug: Telisotuzumab vedotin
Other Name: ABBV-399
- The participant must not be eligible for a telisotuzumab vedotin clinical trial.
ABBVIE CALL CENTER